Sam Morgan, AdipoLABs Healthcare India CEO explains REMISSION 1℃ to South Korean Ambassador Shin Bong-gil in India

On January 23 and 24, SAM MORGAN, CEO of AdipoLABs Healthcare India Pte. Ltd.(a joint venture between AdipoLABs Co., Ltd. in South Korea(CEO Han Sung-ho) and United World Halal Development (UNWHD)), The Tamilnadu Global Investors Meet 2019 held in Chennai, Tamil Nadu, India. Many people paid attention to the REMISSION 1℃ manufactured by Korea's original technology.

REMISSION 1℃ is a medical device developed and manufactured and produced by AdipoLABs, a Korean medical device manufacturer, by using Korean technology. It is a high-frequency hyperthermia cancer treatment device that treats cancer by increasing immunity through deep heat. REMISSION 1°C was approved as a cancer treatment device by the Ministry of Food and Drug Safety(KFDA) in 2015, and also has the US FDA registration, Shariah compliance certification, Halal certification, ISO13485 certification, RoHS certification, etc. MOUs and export inquiries are underway for export from several countries.

In addition, REMISSION 1℃ was introduced to broadcasters such as India and Uzbekistan to attract attention. Oxymed Hospitals in Chennai India, the capital city of Tamil nadu and the National Cancer Center in Gulistan Uzbekistan, the capital city of Sirdaryo viloyati is using REMISSION 1°C. The media reported this case, drawing attention to improved patient cases through this cancer treatment.

AdipoLABs will continue to participate in the Arab Health Exhibition 2019 in Dubai, United Arab Emirates, on January 28-31. And, on March 14-17, they will also participate in the 35th Korea International Medical Equipment Show (KIMES 2019), which will be held at COEX in Seoul. They will hold seminars about REMISSION 1°C’s introduction and case studies on the efficacy on March 15 to attract buyers, medical staff, and patients from Korea and abroad.

REMISSION 1℃, which is being used in university hospitals and nursing hospitals in Korea, including the Catholic University of Korea, Seoul St. Mary's Hospital, is drawing attention in the field of cancer treatment at home and abroad.